@entity791 : simultaneous treatment with combined @entity786 , @entity632 , XXXX , and @entity229 chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.

@entity1 @entity632 @entity778 @entity137 @entity404 @entity146 @entity229 @entity3726 @entity786 @entity1891 @entity1431 @entity1292 @entity791
BACKGROUND: Highly active antiretroviral therapy (HAART) has improved the survival of @entity1 with @entity791 ( @entity791 ). The German @entity791 Study Group investigated whether HAART administered concomitantly with @entity786 , @entity632 , @entity1891 , and @entity229 ( @entity3726 ) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a positive effect on remission and survival. METHODS: From 1997 to 2001, 72 @entity1 with @entity791 were stratified prospectively into a standard-risk group (n = 48 @entity1 ) and a high-risk group (n = 24 @entity1 ) with either 0-1 or 2-3 of the following risk factors: @entity404 < 50/microL, prior @entity1292 , and/or a World Health Organization performance status > or = 3. @entity1 in the high-risk group received > or =75% of the @entity3726 regimen. RESULTS: In the standard-risk group ( @entity404 = 223/muL; age-adjusted International Prognostic Index [aaIPI], 38% > or = 2), the complete remission (CR) rate was 79%, and median survival was not reached after a median 47 months of follow-up. @entity404 counts did not change from baseline to 4 weeks after the end of chemotherapy (206/microL). In the high-risk group ( @entity404 = 34/muL; aaIPI, 88% > or = 2), the CR rate was 29%, and the median survival was 7.2 months (3 @entity1 survived for > 3 yrs). @entity137 was moderate: @entity1431 Grade 3 or 4 occurred in 100 of 249 chemotherapy cycles (40%) in the standard-risk group and in 70 of 102 cycles (69%) in the high-risk group. CONCLUSIONS: Based on the aaIPI, the survival of @entity1 in the standard-risk group was very similar to that achieved by @entity778 @entity1 who had @entity146 . Concurrent @entity3726 plus HAART can be administered in an outpatient setting. Thus, the authors recommend using this modality as first-line therapy for @entity1 with @entity791 .
